{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:11:31Z","timestamp":1789765891335,"version":"4.0.1"},"publisher-location":"Cham","reference-count":119,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031651861","type":"print"},{"value":"9783031651878","type":"electronic"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1007\/978-3-031-65187-8_20","type":"book-chapter","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T03:24:15Z","timestamp":1735615455000},"page":"745-784","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antiviral Agents: Structural Basis of Action and Rational Design"],"prefix":"10.1007","author":[{"given":"Luis","family":"Men\u00e9ndez-Arias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Gago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"issue":"3","key":"20_CR1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1128\/CMR.00102-15","volume":"29","author":"E De Clercq","year":"2016","unstructured":"De Clercq E, Li G (2016) Approved antiviral drugs over the past 50 years. Clin Microbiol Rev 29(3):695\u2013747","journal-title":"Clin Microbiol Rev"},{"key":"20_CR2","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.ijbiomac.2021.01.076","volume":"172","author":"DR Tompa","year":"2021","unstructured":"Tompa DR, Immanuel A, Srikanth S, Kadhirvel S (2021) Trends and strategies to combat viral infections: a review on FDA approved antiviral drugs. Int J Biol Macromol 172:524\u2013541","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"20_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.tips.2021.10.004","volume":"43","author":"L Men\u00e9ndez-Arias","year":"2022","unstructured":"Men\u00e9ndez-Arias L, Delgado R (2022) Update and latest advances in antiretroviral therapy. Trends Pharmacol Sci 43(1):16\u201329","journal-title":"Trends Pharmacol Sci"},{"key":"20_CR4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.pharmthera.2017.10.009","volume":"183","author":"U Spengler","year":"2018","unstructured":"Spengler U (2018) Direct antiviral agents (DAAs) - a new age in the treatment of hepatitis C virus infection. Pharmacol Ther 183:118\u2013126","journal-title":"Pharmacol Ther"},{"issue":"7","key":"20_CR5","doi-asserted-by":"publisher","first-page":"4514","DOI":"10.1039\/D0CS01084G","volume":"50","author":"Y Ma","year":"2021","unstructured":"Ma Y, Frutos-Beltr\u00e1n E, Kang D et al (2021) Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses. Chem Soc Rev 50(7):4514\u20134540","journal-title":"Chem Soc Rev"},{"key":"20_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ijantimicag.2008.10.010","volume":"33","author":"E De Clercq","year":"2009","unstructured":"De Clercq E (2009) Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 33:307\u2013320","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"20_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.antiviral.2013.01.007","volume":"98","author":"L Men\u00e9ndez-Arias","year":"2013","unstructured":"Men\u00e9ndez-Arias L (2013) Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Antiviral Res 98(1):93\u2013120","journal-title":"Antiviral Res"},{"key":"20_CR8","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.3390\/v1031137","volume":"1","author":"L Men\u00e9ndez-Arias","year":"2009","unstructured":"Men\u00e9ndez-Arias L (2009) Mutation rates and intrinsic fidelity of retroviral reverse transcriptases. Viruses 1:1137\u20131165","journal-title":"Viruses"},{"issue":"1","key":"20_CR9","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41598-017-18974-8","volume":"8","author":"A Sebasti\u00e1n-Mart\u00edn","year":"2018","unstructured":"Sebasti\u00e1n-Mart\u00edn A, Barrioluengo V, Men\u00e9ndez-Arias L (2018) Transcriptional inaccuracy threshold attenuates differences in RNA-dependent DNA synthesis fidelity between retroviral reverse transcriptases. Sci Rep 8(1):627","journal-title":"Sci Rep"},{"key":"20_CR10","doi-asserted-by":"publisher","first-page":"305","DOI":"10.4049\/jimmunol.67.4.305","volume":"67","author":"D Hamre","year":"1951","unstructured":"Hamre D, Brownlee KA, Donovick R (1951) Studies on the chemotherapy of vaccinia virus. II. The activity of some thiosemicarbazones. J Immunol 67:305\u2013312","journal-title":"J Immunol"},{"key":"20_CR11","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/S0140-6736(63)90230-7","volume":"2","author":"DJ Bauer","year":"1963","unstructured":"Bauer DJ, St. Vincent L, Kempe CH, Downie AW (1963) Prophylactic treatment of smallpox contacts with N-methylisatin \u03b2-thiosemicarbazone (compound 33T57, Marboran). Lancet 2:494\u2013496","journal-title":"Lancet"},{"key":"20_CR12","doi-asserted-by":"crossref","unstructured":"Prusoff WH (1959) Synthesis and biological activities of iododeoxyuridine, an analog of thymidine. Biochim Biophys Acta 32:295\u2013296","DOI":"10.1016\/0006-3002(59)90597-9"},{"key":"20_CR13","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.drudis.2009.04.005","volume":"14","author":"AM Jordan","year":"2009","unstructured":"Jordan AM, Roughley SD (2009) Drug discovery chemistry: a primer for the non-specialist. Drug Discov Today 14:731\u2013744","journal-title":"Drug Discov Today"},{"key":"20_CR14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.coph.2016.08.014","volume":"30","author":"M Bassetto","year":"2016","unstructured":"Bassetto M, Massarotti A, Coluccia A, Brancale A (2016) Structural biology in antiviral drug discovery. Curr Opin Pharmacol 30:116\u2013130","journal-title":"Curr Opin Pharmacol"},{"key":"20_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2022.101258","volume":"56","author":"PD Nagy","year":"2022","unstructured":"Nagy PD (2022) Co-opted membranes, lipids, and host proteins: what have we learned from tombusviruses? Curr Opin Virol 56:101258","journal-title":"Curr Opin Virol"},{"key":"20_CR16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/978-981-10-7230-7_6","volume":"1045","author":"K Shiraki","year":"2018","unstructured":"Shiraki K (2018) Antiviral drugs against alphaherpesvirus. Adv Exp Med Biol 1045:103\u2013122","journal-title":"Adv Exp Med Biol"},{"key":"20_CR17","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nrd1877","volume":"4","author":"E De Clercq","year":"2005","unstructured":"De Clercq E, Hol\u00fd A (2005) Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug Discov 4:928\u2013940","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"20_CR18","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1128\/AAC.46.8.2381-2386.2002","volume":"46","author":"JR Beadle","year":"2002","unstructured":"Beadle JR, Hartline C, Aldern KA et al (2002) Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob Agents Chemother 46(8):2381\u20132386","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"20_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0163-7258(89)90097-1","volume":"40","author":"B Oberg","year":"1989","unstructured":"Oberg B (1989) Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacol Ther 40(2):213\u2013285","journal-title":"Pharmacol Ther"},{"key":"20_CR20","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.virusres.2007.12.015","volume":"134","author":"L Men\u00e9ndez-Arias","year":"2008","unstructured":"Men\u00e9ndez-Arias L (2008) Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase. Virus Res 134:124\u2013146","journal-title":"Virus Res"},{"key":"20_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.virusres.2016.12.019","volume":"234","author":"L Men\u00e9ndez-Arias","year":"2017","unstructured":"Men\u00e9ndez-Arias L, Sebasti\u00e1n-Mart\u00edn A, \u00c1lvarez M (2017) Viral reverse transcriptases. Virus Res 234:153\u2013176","journal-title":"Virus Res"},{"key":"20_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.sbi.2019.11.011","volume":"61","author":"F Xavier Ruiz","year":"2020","unstructured":"Xavier Ruiz F, Arnold E (2020) Evolving understanding of HIV-1 reverse transcriptase structure, function, inhibition, and resistance. Curr Opin Struct Biol 61:113\u2013123","journal-title":"Curr Opin Struct Biol"},{"key":"20_CR23","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1021\/jm040127p","volume":"48","author":"BL De Corte","year":"2005","unstructured":"De Corte BL (2005) From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): Fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. J Med Chem 48:1689\u20131696","journal-title":"J Med Chem"},{"issue":"6","key":"20_CR24","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.apsb.2019.11.010","volume":"10","author":"C Zhuang","year":"2020","unstructured":"Zhuang C, Pannecouque C, De Clercq E, Chen F (2020) Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years. Acta Pharm Sin B 10(6):961\u2013978","journal-title":"Acta Pharm Sin B"},{"issue":"7","key":"20_CR25","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021386","volume":"5","author":"J Hu","year":"2015","unstructured":"Hu J, Seeger C (2015) Hepadnavirus genome replication and persistence. Cold Spring Harb Perspect Med 5(7):a021386","journal-title":"Cold Spring Harb Perspect Med"},{"key":"20_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coviro.2014.04.005","volume":"8","author":"L Men\u00e9ndez-Arias","year":"2014","unstructured":"Men\u00e9ndez-Arias L, \u00c1lvarez M, Pacheco B (2014) Nucleoside\/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance. Curr Opin Virol 8:1\u20139","journal-title":"Curr Opin Virol"},{"key":"20_CR27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/nyas.12832","volume":"1358","author":"E Lawitz","year":"2015","unstructured":"Lawitz E, Jacobson IM, Nelson DR et al (2015) Development of sofosbuvir for the treatment of hepatitis C virus infection. Ann N Y Acad Sci 1358:56\u201367","journal-title":"Ann N Y Acad Sci"},{"issue":"19","key":"20_CR28","doi-asserted-by":"publisher","first-page":"7202","DOI":"10.1021\/jm100863x","volume":"53","author":"MJ Sofia","year":"2010","unstructured":"Sofia MJ, Bao D, Chang W et al (2010) Discovery of a \u03b2-d-2'-deoxy-2'-\u03b1-fluoro-2'-\u03b2-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 53(19):7202\u20137218","journal-title":"J Med Chem"},{"issue":"11","key":"20_CR29","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1002\/cmdc.200900289","volume":"4","author":"Y Mehellou","year":"2009","unstructured":"Mehellou Y, Balzarini J, McGuigan C (2009) Aryloxy phosphoramidate triesters: a technology for delivering monophosphorylated nucleosides and sugars into cells. Chem Med Chem 4(11):1779\u20131791","journal-title":"Chem Med Chem"},{"issue":"6","key":"20_CR30","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1021\/acs.jmedchem.7b00734","volume":"61","author":"Y Mehellou","year":"2018","unstructured":"Mehellou Y, Rattan HS, Balzarini J (2018) The ProTide prodrug technology: from the concept to the clinic. J Med Chem 61(6):2211\u20132226","journal-title":"J Med Chem"},{"key":"20_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","volume":"125","author":"AS Ray","year":"2016","unstructured":"Ray AS, Fordyce MW, Hitchcock MJ (2016) Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus. Antiviral Res 125:63\u201370","journal-title":"Antiviral Res"},{"issue":"20","key":"20_CR32","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","volume":"295","author":"CJ Gordon","year":"2020","unstructured":"Gordon CJ, Tchesnokov EP, Woolner E et al (2020) Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem 295(20):6785\u20136797","journal-title":"J Biol Chem"},{"key":"20_CR33","doi-asserted-by":"publisher","first-page":"43395","DOI":"10.1038\/srep43395","volume":"7","author":"MK Lo","year":"2017","unstructured":"Lo MK, Jordan R, Arvey A et al (2017) GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci Rep 7:43395","journal-title":"Sci Rep"},{"key":"20_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104899","volume":"182","author":"E Konkolova","year":"2020","unstructured":"Konkolova E, Dejmek M, H\u0159ebabeck\u00fd H et al (2020) Remdesivir triphosphate can efficiently inhibit the RNA-dependent RNA polymerase from various flaviviruses. Antiviral Res 182:104899","journal-title":"Antiviral Res"},{"key":"20_CR35","doi-asserted-by":"publisher","first-page":"e00162\u201320","DOI":"10.1128\/CMR.00162-20","volume":"34","author":"JJ Malin","year":"2020","unstructured":"Malin JJ, Su\u00e1rez I, Priesner V et al (2020) Remdesivir against COVID-19 and other viral diseases. Clin Microbiol Rev 34:e00162\u201320","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"20_CR36","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1128\/AAC.04619-14","volume":"59","author":"W Kati","year":"2015","unstructured":"Kati W, Koev G, Irvin M et al (2015) In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother 59(3):1505\u20131511","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"20_CR37","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3390\/v14040841","volume":"14","author":"I Hadj Hassine","year":"2022","unstructured":"Hadj Hassine I, Ben M\u2019hadheb M, Men\u00e9ndez-Arias L (2022) Lethal mutagenesis of RNA viruses and approved drugs with antiviral mutagenic activity. Viruses 14(4):841","journal-title":"Viruses"},{"issue":"9","key":"20_CR38","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a038398","volume":"10","author":"E Fodor","year":"2020","unstructured":"Fodor E, Te Velthuis AJW (2020) Structure and function of the influenza virus transcription and replication machinery. Cold Spring Harb Perspect Med 10(9):a038398","journal-title":"Cold Spring Harb Perspect Med"},{"key":"20_CR39","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coviro.2019.01.006","volume":"35","author":"R O\u2019Hanlon","year":"2019","unstructured":"O\u2019Hanlon R, Shaw ML (2019) Baloxavir marboxil: the new influenza drug on the market. Curr Opin Virol 35:14\u201318","journal-title":"Curr Opin Virol"},{"issue":"2","key":"20_CR40","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/femsre\/fuy004","volume":"42","author":"G Ligat","year":"2018","unstructured":"Ligat G, Cazal R, Hantz S, Alain S (2018) The human cytomegalovirus terminase complex as an antiviral target: a close-up view. FEMS Microbiol Rev 42(2):137\u2013145","journal-title":"FEMS Microbiol Rev"},{"key":"20_CR41","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.antiviral.2018.11.005","volume":"161","author":"BG Gentry","year":"2019","unstructured":"Gentry BG, Bogner E, Drach JC (2019) Targeting the terminase: an important step forward in the treatment and prophylaxis of human cytomegalovirus infections. Antiviral Res 161:116\u2013124","journal-title":"Antiviral Res"},{"key":"20_CR42","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.antiviral.2019.01.011","volume":"163","author":"J Piret","year":"2019","unstructured":"Piret J, Boivin G (2019) Clinical development of letermovir and maribavir: overview of human cytomegalovirus drug resistance. Antiviral Res 163:91\u2013105","journal-title":"Antiviral Res"},{"issue":"2","key":"20_CR43","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3390\/v13020205","volume":"13","author":"SJ Smith","year":"2021","unstructured":"Smith SJ, Zhao XZ, Passos DO et al (2021) Integrase strand transfer inhibitors are effective anti-HIV drugs. Viruses 13(2):205","journal-title":"Viruses"},{"issue":"1","key":"20_CR44","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41579-021-00586-9","volume":"20","author":"GN Maertens","year":"2022","unstructured":"Maertens GN, Engelman AN, Cherepanov P (2022) Structure and function of retroviral integrase. Nat Rev Microbiol 20(1):20\u201334","journal-title":"Nat Rev Microbiol"},{"key":"20_CR45","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/nyas.12218","volume":"1291","author":"DJ Hazuda","year":"2013","unstructured":"Hazuda DJ, Burroughs M, Howe AY et al (2013) Development of boceprevir: a first-in-class direct antiviral treatment for chronic hepatitis C infection. Ann N Y Acad Sci 1291:69\u201376","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"20_CR46","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/s41564-023-01356-4","volume":"8","author":"SS Toussi","year":"2023","unstructured":"Toussi SS, Hammond JL, Gerstenberger BS, Anderson AS (2023) Therapeutics for COVID-19. Nat Microbiol 8(5):771\u2013786","journal-title":"Nat Microbiol"},{"issue":"9","key":"20_CR47","doi-asserted-by":"publisher","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","volume":"65","author":"Y Unoh","year":"2022","unstructured":"Unoh Y, Uehara S, Nakahara K et al (2022) Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J Med Chem 65(9):6499\u20136512","journal-title":"J Med Chem"},{"key":"20_CR48","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature08960","volume":"465","author":"M Gao","year":"2010","unstructured":"Gao M, Nettles RE, Belema M et al (2010) Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:96\u2013100","journal-title":"Nature"},{"key":"20_CR49","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.drup.2018.01.004","volume":"37","author":"MC Sorbo","year":"2018","unstructured":"Sorbo MC, Cento V, Di Maio VC et al (2018) Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. Drug Resist Updat 37:17\u201339","journal-title":"Drug Resist Updat"},{"issue":"1","key":"20_CR50","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/COH.0000000000000713","volume":"17","author":"H Dvory-Sobol","year":"2022","unstructured":"Dvory-Sobol H, Shaik N, Callebaut C, Rhee MS (2022) Lenacapavir: a first-in-class HIV-1 capsid inhibitor. Curr Opin HIV AIDS 17(1):15\u201321","journal-title":"Curr Opin HIV AIDS"},{"issue":"1","key":"20_CR51","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12977-021-00583-z","volume":"18","author":"WM McFadden","year":"2021","unstructured":"McFadden WM, Snyder AA, Kirby KA et al (2021) Rotten to the core: antivirals targeting the HIV-1 capsid core. Retrovirology 18(1):41","journal-title":"Retrovirology"},{"issue":"1","key":"20_CR52","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a038455","volume":"12","author":"L Gubareva","year":"2022","unstructured":"Gubareva L, Mohan T (2022) Antivirals targeting the neuraminidase. Cold Spring Harb Perspect Med 12(1):a038455","journal-title":"Cold Spring Harb Perspect Med"},{"key":"20_CR53","doi-asserted-by":"publisher","first-page":"28403","DOI":"10.1074\/jbc.R110.129809","volume":"285","author":"SJ Gamblin","year":"2010","unstructured":"Gamblin SJ, Skehel JJ (2010) Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem 285:28403\u201328409","journal-title":"J Biol Chem"},{"key":"20_CR54","doi-asserted-by":"crossref","unstructured":"Almehmadi M, Allahyani M, Alsaiari AA et al (2022, 1870) A glance at the development and patent literature of tecovirimat: the first-in-class therapy for emerging monkeypox outbreak. Viruses 14(9):1870","DOI":"10.3390\/v14091870"},{"issue":"7","key":"20_CR55","doi-asserted-by":"publisher","first-page":"4468","DOI":"10.1021\/acs.jmedchem.3c00069","volume":"66","author":"J Wang","year":"2023","unstructured":"Wang J, Shahed-Ai-Mahmud M, Chen A et al (2023) An overview of antivirals against monkeypox virus and other orthopoxviruses. J Med Chem 66(7):4468\u20134490","journal-title":"J Med Chem"},{"key":"20_CR56","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1743-422X-6-44","volume":"6","author":"Y Chen","year":"2009","unstructured":"Chen Y, Honeychurch KM, Yang G et al (2009) Vaccinia virus p37 interacts with host proteins associated with LE-derived transport vesicle biogenesis. Virol J 6:44","journal-title":"Virol J"},{"issue":"5","key":"20_CR57","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/jac\/dku545","volume":"70","author":"S Duraffour","year":"2015","unstructured":"Duraffour S, Lorenzo MM, Z\u00f6ller G et al (2015) ST-246 is a key antiviral to inhibit the viral F13L phospholipase, one of the essential proteins for orthopoxvirus wrapping. J Antimicrob Chemother 70(5):1367\u20131380","journal-title":"J Antimicrob Chemother"},{"key":"20_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114414","volume":"237","author":"O Mart\u00ed-Mar\u00ed","year":"2022","unstructured":"Mart\u00ed-Mar\u00ed O, Mart\u00ednez-Gualda B, Fern\u00e1ndez-Barahona I et al (2022) Organotropic dendrons with high potency as HIV-1, HIV-2 and EV-A71 cell entry inhibitors. Eur J Med Chem 237:114414","journal-title":"Eur J Med Chem"},{"key":"20_CR59","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.1021\/jm3002247","volume":"55","author":"F Curreli","year":"2012","unstructured":"Curreli F, Choudhury S, Pyatkin I et al (2012) Design, synthesis, and antiviral activity of entry inhibitors that target the CD4-binding site of HIV-1. J Med Chem 55:4764\u20134775","journal-title":"J Med Chem"},{"issue":"17","key":"20_CR60","doi-asserted-by":"publisher","first-page":"6909","DOI":"10.1021\/acs.jmedchem.5b00709","volume":"58","author":"F Curreli","year":"2015","unstructured":"Curreli F, Kwon YD, Zhang H et al (2015) Structure-based design of a small molecule CD4-antagonist with broad spectrum anti-HIV-1 activity. J Med Chem 58(17):6909\u20136927","journal-title":"J Med Chem"},{"issue":"11","key":"20_CR61","first-page":"1955","volume":"30","author":"T Wang","year":"2021","unstructured":"Wang T, Kadow JF, Meanwell NA (2021) Innovation in the discovery of the HIV-1 attachment inhibitor temsavir and its phosphonooxymethyl prodrug fostemsavir. Med Chem Res 30(11):1955\u20131980","journal-title":"Med Chem Res"},{"issue":"1","key":"20_CR62","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/COH.0000000000000712","volume":"17","author":"PM Grant","year":"2022","unstructured":"Grant PM, Kozal MJ (2022) Fostemsavir: a first-in-class HIV-1 attachment inhibitor. Curr Opin HIV AIDS 17(1):32\u201335","journal-title":"Curr Opin HIV AIDS"},{"issue":"2","key":"20_CR63","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/prot.24726","volume":"83","author":"DR Langley","year":"2015","unstructured":"Langley DR, Kimura SR, Sivaprakasam P et al (2015) Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action. Proteins 83(2):331\u2013350","journal-title":"Proteins"},{"issue":"6","key":"20_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010547","volume":"18","author":"DC Files","year":"2022","unstructured":"Files DC, Tacke F, O\u2019Sullivan A et al (2022) Rationale of using the dual chemokine receptor CCR2\/CCR5 inhibitor cenicriviroc for the treatment of COVID-19. PLoS Pathog 18(6):e1010547","journal-title":"PLoS Pathog"},{"issue":"6","key":"20_CR65","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2174\/1570162X19666210908115231","volume":"19","author":"A Monteiro","year":"2021","unstructured":"Monteiro A, Yu KOA, Hicar MD (2021) Peptide-based fusion inhibitors for preventing the six-helix bundle formation of class I fusion proteins: HIV and beyond. Curr HIV Res 19(6):465\u2013475","journal-title":"Curr HIV Res"},{"key":"20_CR66","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.sbi.2017.10.010","volume":"48","author":"P \u015aled\u017a","year":"2018","unstructured":"\u015aled\u017a P, Caflisch A (2018) Protein structure-based drug design: from docking to molecular dynamics. Curr Opin Struct Biol 48:93\u2013102","journal-title":"Curr Opin Struct Biol"},{"key":"20_CR67","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/978-1-0716-2855-3_7","volume":"2601","author":"W Yu","year":"2023","unstructured":"Yu W, Weber DJ, MacKerell AD Jr (2023) Computer-aided drug design: an update. Methods Mol Biol 2601:123\u2013152","journal-title":"Methods Mol Biol"},{"key":"20_CR68","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cbpa.2018.06.006","volume":"44","author":"BM Wingert","year":"2018","unstructured":"Wingert BM, Camacho CJ (2018) Improving small molecule virtual screening strategies for the next generation of therapeutics. Curr Opin Chem Biol 44:87\u201392","journal-title":"Curr Opin Chem Biol"},{"issue":"12","key":"20_CR69","doi-asserted-by":"publisher","first-page":"6065","DOI":"10.1021\/acs.jcim.0c00675","volume":"60","author":"JJ Irwin","year":"2020","unstructured":"Irwin JJ, Tang KG, Young J et al (2020) ZINC20-A free ultralarge-scale chemical database for ligand discovery. J Chem Inf Model 60(12):6065\u20136073","journal-title":"J Chem Inf Model"},{"key":"20_CR70","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"CA Lipinski","year":"2001","unstructured":"Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3\u201326","journal-title":"Adv Drug Deliv Rev"},{"key":"20_CR71","doi-asserted-by":"crossref","unstructured":"Koes DR, Camacho CJ (2012) ZINCPharmer: pharmacophore search of the ZINC database. Nucleic Acids Res 40(Web Server issue):W409-414","DOI":"10.1093\/nar\/gks378"},{"issue":"4","key":"20_CR72","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1021\/acs.jmedchem.6b01437","volume":"60","author":"Y Hu","year":"2017","unstructured":"Hu Y, Stumpfe D, Bajorath J (2017) Recent advances in scaffold hopping. J Med Chem 60(4):1238\u20131246","journal-title":"J Med Chem"},{"issue":"2","key":"20_CR73","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/med.21862","volume":"42","author":"G Macip","year":"2022","unstructured":"Macip G, Garcia-Segura P, Mestres-Truyol J et al (2022) Haste makes waste: a critical review of docking-based virtual screening in drug repurposing for SARS-CoV-2 main protease (M-pro) inhibition. Med Res Rev 42(2):744\u2013769","journal-title":"Med Res Rev"},{"issue":"22","key":"20_CR74","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1021\/acs.jcim.1c00096","volume":"62","author":"F Boyles","year":"2022","unstructured":"Boyles F, Deane CM, Morris GM (2022) Learning from docked ligands: ligand-based features rescue structure-based scoring functions when trained on docked poses. J Chem Inf Model 62(22):5329\u20135341","journal-title":"J Chem Inf Model"},{"issue":"5","key":"20_CR75","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1021\/acs.jmedchem.0c02227","volume":"64","author":"A Fischer","year":"2021","unstructured":"Fischer A, Smie\u0161ko M, Sellner M, Lill MA (2021) Decision making in structure-based drug discovery: visual inspection of docking results. J Med Chem 64(5):2489\u20132500","journal-title":"J Med Chem"},{"issue":"6557","key":"20_CR76","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1126\/science.abj8754","volume":"373","author":"M Baek","year":"2021","unstructured":"Baek M, DiMaio F, Anishchenko I et al (2021) Accurate prediction of protein structures and interactions using a three-track neural network. Science 373(6557):871\u2013876","journal-title":"Science"},{"issue":"7873","key":"20_CR77","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper J, Evans R, Pritzel A et al (2021) Highly accurate protein structure prediction with AlphaFold. Nature 596(7873):583\u2013589","journal-title":"Nature"},{"key":"20_CR78","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/nrd1549","volume":"3","author":"DB Kitchen","year":"2004","unstructured":"Kitchen DB, Decornez H, Furr JR, Bajorath J (2004) Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discover 3:935\u2013949","journal-title":"Nat Rev Drug Discover"},{"key":"20_CR79","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2174\/092986708783330683","volume":"15","author":"RV Guido","year":"2008","unstructured":"Guido RV, Oliva G, Andricopulo AD (2008) Virtual screening and its integration with modern drug design technologies. Curr Med Chem 15:37\u201346","journal-title":"Curr Med Chem"},{"key":"20_CR80","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10822-011-9451-z","volume":"25","author":"C Sun","year":"2011","unstructured":"Sun C, Petros AM, Hajduk PJ (2011) Fragment-based lead discovery: challenges and opportunities. J Comput Aided Mol Des 25:607\u2013610","journal-title":"J Comput Aided Mol Des"},{"key":"20_CR81","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.drudis.2010.08.004","volume":"15","author":"C Abad-Zapatero","year":"2010","unstructured":"Abad-Zapatero C, Peri\u0161i\u0107 O, Wass J et al (2010) Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation. Drug Discov Today 15:804\u2013811","journal-title":"Drug Discov Today"},{"key":"20_CR82","doi-asserted-by":"publisher","first-page":"W387","DOI":"10.1093\/nar\/gks336","volume":"40","author":"DR Koes","year":"2012","unstructured":"Koes DR, Camacho CJ (2012) PocketQuery: protein-protein interaction inhibitor starting points from protein-protein interaction structure. Nucleic Acids Res 40:W387\u2013W392","journal-title":"Nucleic Acids Res"},{"key":"20_CR83","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1021\/ci200468p","volume":"52","author":"DR Hall","year":"2012","unstructured":"Hall DR, Ngan CH, Zerbe BS et al (2012) Hot spot analysis for driving the development of hits into leads in fragment-based drug discovery. J Chem Inf Model 52:199\u2013209","journal-title":"J Chem Inf Model"},{"key":"20_CR84","doi-asserted-by":"crossref","unstructured":"Morreale A, Gago F (2012) Chapter 10: COMparative BINding Energy (COMBINE) analysis as a structure-based 3D-QSAR method. In: Luque J, Barril X (eds) Physico-chemical and computational approaches to drug discovery. Royal Society of Chemistry","DOI":"10.1039\/9781849735377-00244"},{"issue":"9208","key":"20_CR85","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/S0140-6736(05)74775-9","volume":"355","author":"TN Raju","year":"2000","unstructured":"Raju TN (2000) The Nobel chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918-99), and George H Hitchings (1905-98). Lancet 355(9208):1022","journal-title":"Lancet"},{"issue":"12","key":"20_CR86","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s10822-021-00430-5","volume":"35","author":"RA Lewis","year":"2021","unstructured":"Lewis RA (2021) Best practices for repurposing studies. J Comput Aided Mol Des 35(12):1189\u20131193","journal-title":"J Comput Aided Mol Des"},{"issue":"3","key":"20_CR87","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1021\/acscentsci.1c00039","volume":"7","author":"CH Zhang","year":"2021","unstructured":"Zhang CH, Stone EA, Deshmukh M et al (2021) Potent noncovalent inhibitors of the main protease of SARS-CoV-2 from molecular sculpting of the drug perampanel guided by free energy perturbation calculations. ACS Cent Sci 7(3):467\u2013475","journal-title":"ACS Cent Sci"},{"key":"20_CR88","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/303035a0","volume":"303","author":"JN Varghese","year":"1983","unstructured":"Varghese JN, Laver WG, Colman PM (1983) Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 \u00c5 resolution. Nature 303:35\u201340","journal-title":"Nature"},{"key":"20_CR89","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nrd2400","volume":"6","author":"M Von Itzstein","year":"2007","unstructured":"Von Itzstein M (2007) The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov 6:967\u2013974","journal-title":"Nat Rev Drug Discov"},{"key":"20_CR90","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1126\/science.2183354","volume":"248","author":"NA Roberts","year":"1990","unstructured":"Roberts NA, Martin JA, Kinchington D et al (1990) Rational design of peptide-based HIV proteinase inhibitors. Science 248:358\u2013361","journal-title":"Science"},{"key":"20_CR91","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/anie.201102762","volume":"51","author":"AK Ghosh","year":"2012","unstructured":"Ghosh AK, Anderson DD, Weber IT, Mitsuya H (2012) Enhancing protein backbone binding \u2013 a fruitful concept for combating drug-resistant HIV. Angew Chem Int Ed Engl 51:1778\u20131802","journal-title":"Angew Chem Int Ed Engl"},{"issue":"5","key":"20_CR92","doi-asserted-by":"publisher","first-page":"839","DOI":"10.3390\/v13050839","volume":"13","author":"IT Weber","year":"2021","unstructured":"Weber IT, Wang YF, Harrison RW (2021) HIV protease: historical perspective and current research. Viruses 13(5):839","journal-title":"Viruses"},{"key":"20_CR93","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.antiviral.2006.03.011","volume":"71","author":"AK Patick","year":"2006","unstructured":"Patick AK (2006) Rhinovirus chemotherapy. Antiviral Res 71:391\u2013396","journal-title":"Antiviral Res"},{"key":"20_CR94","doi-asserted-by":"publisher","first-page":"4848","DOI":"10.1128\/JVI.76.10.4848-4854.2002","volume":"76","author":"A Zlotnick","year":"2002","unstructured":"Zlotnick A, Ceres P, Singh S, Johnson JM (2002) A small molecule inhibits and misdirects assembly of hepatitis B virus capsids. J Virol 76:4848\u20134854","journal-title":"J Virol"},{"key":"20_CR95","doi-asserted-by":"publisher","first-page":"8138","DOI":"10.1073\/pnas.0409732102","volume":"102","author":"SJ Stray","year":"2005","unstructured":"Stray SJ, Bourne CR, Punna S et al (2005) A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. Proc Natl Acad Sci USA 102:8138\u20138143","journal-title":"Proc Natl Acad Sci USA"},{"key":"20_CR96","doi-asserted-by":"publisher","first-page":"11055","DOI":"10.1128\/JVI.00933-06","volume":"80","author":"CR Bourne","year":"2006","unstructured":"Bourne CR, Finn MG, Zlotnick A (2006) Global structural changes in hepatitis B virus capsids induced by the assembly effector HAP1. J Virol 80:11055\u201311061","journal-title":"J Virol"},{"issue":"3","key":"20_CR97","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.bmc.2016.12.017","volume":"25","author":"Q Ren","year":"2017","unstructured":"Ren Q, Liu X, Luo Z et al (2017) Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4). Bioorg Med Chem 25(3):1042\u20131056","journal-title":"Bioorg Med Chem"},{"key":"20_CR98","doi-asserted-by":"crossref","unstructured":"Feng S, Gao L, Han X et al (2018) Discovery of small molecule therapeutics for treatment of chronic HBV infection. ACS Infect Dis 4(3):257\u2013277","DOI":"10.1021\/acsinfecdis.7b00144"},{"issue":"8","key":"20_CR99","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.str.2013.06.013","volume":"21","author":"SP Katen","year":"2013","unstructured":"Katen SP, Tan Z, Chirapu SR et al (2013) Assembly-directed antivirals differentially bind quasiequivalent pockets to modify hepatitis B virus capsid tertiary and quaternary structure. Structure 21(8):1406\u20131416","journal-title":"Structure"},{"issue":"12","key":"20_CR100","doi-asserted-by":"publisher","first-page":"6931","DOI":"10.1128\/JVI.00582-13","volume":"87","author":"MR Campagna","year":"2013","unstructured":"Campagna MR, Liu F, Mao R et al (2013) Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids. J Virol 87(12):6931\u20136942","journal-title":"J Virol"},{"issue":"3","key":"20_CR101","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1053\/j.gastro.2017.10.017","volume":"154","author":"K Klumpp","year":"2018","unstructured":"Klumpp K, Shimada T, Allweiss L et al (2018) Efficacy of NVR 3-778, alone and in combination with pegylated interferon, vs entecavir in uPA\/SCID mice with humanized livers and HBV infection. Gastroenterology 154(3):652\u2013662.e8","journal-title":"Gastroenterology"},{"key":"20_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112714","volume":"206","author":"Y Ren","year":"2020","unstructured":"Ren Y, Ma Y, Cherukupalli S et al (2020) Discovery and optimization of benzenesulfonamides-based hepatitis B virus capsid modulators via contemporary medicinal chemistry strategies. Eur J Med Chem 206:112714","journal-title":"Eur J Med Chem"},{"key":"20_CR103","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cbpa.2019.02.009","volume":"50","author":"B Nijampatnam","year":"2019","unstructured":"Nijampatnam B, Liotta DC (2019) Recent advances in the development of HBV capsid assembly modulators. Curr Opin Chem Biol 50:73\u201379","journal-title":"Curr Opin Chem Biol"},{"key":"20_CR104","doi-asserted-by":"crossref","unstructured":"Berke JM, Dehertogh P, Vergauwen K et al (2020) Antiviral properties and mechanism of action studies of the hepatitis B virus capsid assembly modulator JNJ-56136379. Antimicrob Agents Chemother 64(5):e02439\u201319","DOI":"10.1128\/AAC.02439-19"},{"key":"20_CR105","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1146\/annurev-med-080119-103356","volume":"72","author":"S Naggie","year":"2021","unstructured":"Naggie S, Lok AS (2021) New therapeutics for hepatitis B: the road to cure. Annu Rev Med 72:93\u2013105","journal-title":"Annu Rev Med"},{"issue":"7","key":"20_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103617","volume":"28","author":"Y Jin","year":"2023","unstructured":"Jin Y, Wang S, Xu S et al (2023) Targeting hepatitis B virus cccDNA levels: recent progress in seeking small molecule drug candidates. Drug Discov Today 28(7):103617","journal-title":"Drug Discov Today"},{"key":"20_CR107","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.drudis.2008.02.003","volume":"13","author":"CS Adamson","year":"2008","unstructured":"Adamson CS, Freed EO (2008) Recent progress in antiretrovirals \u2013 lessons from resistance. Drug Discov Today 13:424\u2013432","journal-title":"Drug Discov Today"},{"key":"20_CR108","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.jmb.2011.03.074","volume":"410","author":"PE Prevelige Jr","year":"2011","unstructured":"Prevelige PE Jr (2011) New approaches for antiviral targeting of HIV assembly. J Mol Biol 410:634\u2013640","journal-title":"J Mol Biol"},{"key":"20_CR109","doi-asserted-by":"publisher","first-page":"5080","DOI":"10.1128\/AAC.00759-09","volume":"53","author":"WS Blair","year":"2009","unstructured":"Blair WS, Cao J, Fok-Seang J et al (2009) New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation. Antimicrob Agents Chemother 53:5080\u20135087","journal-title":"Antimicrob Agents Chemother"},{"key":"20_CR110","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.cell.2009.04.063","volume":"137","author":"O Pornillos","year":"2009","unstructured":"Pornillos O, Ganser-Pornillos BK, Kelly BN et al (2009) X-ray structures of the hexameric building block of the HIV capsid. Cell 137:1282\u20131292","journal-title":"Cell"},{"issue":"2","key":"20_CR111","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.virusres.2012.06.016","volume":"169","author":"R Bocanegra","year":"2012","unstructured":"Bocanegra R, Rodr\u00edguez-Huete A, Fuertes M\u00c1 et al (2012) Molecular recognition in the human immunodeficiency virus capsid and antiviral design. Virus Res 169(2):388\u2013410","journal-title":"Virus Res"},{"key":"20_CR112","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.38895","volume":"7","author":"M Obr","year":"2018","unstructured":"Obr M, Kr\u00e4usslich HG (2018) The secrets of the stability of the HIV-1 capsid. Elife 7:e38895","journal-title":"Elife"},{"key":"20_CR113","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1128\/JVI.01406-10","volume":"85","author":"J Shi","year":"2011","unstructured":"Shi J, Zhou J, Shah VB et al (2011) Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization. J Virol 85:542\u2013549","journal-title":"J Virol"},{"key":"20_CR114","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001220","volume":"6","author":"WS Blair","year":"2010","unstructured":"Blair WS, Pickford C, Irving SL et al (2010) HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS Pathog 6:e1001220","journal-title":"PLoS Pathog"},{"key":"20_CR115","doi-asserted-by":"publisher","first-page":"6643","DOI":"10.1128\/JVI.00493-12","volume":"86","author":"CT Lemke","year":"2012","unstructured":"Lemke CT, Titolo S, von Schwedler U et al (2012) Distinct effects of two HIV-1 capsid assembly inhibitor families that bind the same site within the N-terminal domain of the viral CA protein. J Virol 86:6643\u20136655","journal-title":"J Virol"},{"issue":"6514","key":"20_CR116","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1126\/science.abb4808","volume":"370","author":"SM Bester","year":"2020","unstructured":"Bester SM, Wei G, Zhao H et al (2020) Structural and mechanistic bases for a potent HIV-1 capsid inhibitor. Science 370(6514):360\u2013364","journal-title":"Science"},{"issue":"4","key":"20_CR117","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1093\/jac\/dkab503","volume":"77","author":"N Margot","year":"2022","unstructured":"Margot N, Vanderveen L, Naik V et al (2022) Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study. J Antimicrob Chemother 77(4):989\u2013995","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"20_CR118","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1093\/infdis\/jiac364","volume":"226","author":"NA Margot","year":"2022","unstructured":"Margot NA, Naik V, VanderVeen L et al (2022) Resistance analyses in highly treatment-experienced people with human immunodeficiency virus (HIV) treated with the novel capsid HIV inhibitor lenacapavir. J Infect Dis 226(11):1985\u20131991","journal-title":"J Infect Dis"},{"issue":"5","key":"20_CR119","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01804-22","volume":"13","author":"SM Bester","year":"2022","unstructured":"Bester SM, Adu-Ampratwum D, Annamalai AS et al (2022) Structural and mechanistic bases of viral resistance to HIV-1 capsid inhibitor lenacapavir. mBio 13(5):e0180422","journal-title":"mBio"}],"container-title":["Subcellular Biochemistry","Structure and Physics of Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-65187-8_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T05:00:31Z","timestamp":1735621231000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-65187-8_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9783031651861","9783031651878"],"references-count":119,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-65187-8_20","relation":{},"ISSN":["0306-0225","2542-8810"],"issn-type":[{"value":"0306-0225","type":"print"},{"value":"2542-8810","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"31 December 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}